REDWOOD CITY, Calif., Dec. 28 /PRNewswire/ -- Codexis, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of shares of its common stock. The shares of common stock to be sold in this offering are proposed to be sold by Codexis, Inc. and certain of its stockholders.
Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co. will be acting as joint book-running managers, with RBC Capital Markets Corporation and Pacific Crest Securities LLC acting as co-managers for the offering. This offering will be made only by means of a prospectus. Copies of the preliminary prospectus for this offering may be obtained, when available, from the prospectus department of Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York 10010, via telephone at 1-800-221-1037; or from the prospectus department of Goldman, Sachs & Co., Attention: Prospectus Department, 85 Broad Street, New York, New York 10004, via telephone at 1-866-471-2526 or via fax at 212-902-9316.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall neither constitute an offer to sell nor a solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Codexis
Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and has the potential to make new industrial processes possible at commercial scale. Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals.
Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144
